Free Trial
NASDAQ:CLSD

Clearside Biomedical Q2 2024 Earnings Report

Clearside Biomedical logo
$0.43 +0.01 (+2.79%)
Closing price 04:00 PM Eastern
Extended Trading
$0.42 -0.01 (-2.04%)
As of 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearside Biomedical EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.04
One Year Ago EPS
-$0.15

Clearside Biomedical Revenue Results

Actual Revenue
$0.09 million
Expected Revenue
$0.25 million
Beat/Miss
Missed by -$160.00 thousand
YoY Revenue Growth
N/A

Clearside Biomedical Announcement Details

Quarter
Q2 2024
Time
After Market Closes
Conference Call Date
Monday, August 12, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Clearside Biomedical's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Clearside Biomedical Earnings Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
See More Clearside Biomedical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email.

About Clearside Biomedical

Clearside Biomedical (NASDAQ:CLSD), a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

View Clearside Biomedical Profile

More Earnings Resources from MarketBeat